miR-29b enhances the proliferation and migration of bone marrow mesenchymal stem cells in rats with castration-induced osteoporosis through the PI3K/AKT and TGF-β/Smad signaling pathways

YUHUI WANG1*, XIANGMIN HAN2*, TONGXIN ZANG3, PING KANG4, WEI JIANG5 and NIU NIU6

1Department of Clinical Laboratory, Affiliated Hospital of Beihua University, Jilin, Jilin 132011; 2Department of Clinical Laboratory, Jinan Zhangqiu District Hospital of TCM, Jinan, Shandong 250200; 3Department of Orthopaedics, Qingdao Central Hospital, Qingdao University, Qingdao, Shandong 266042; Departments of 4Rehabilitation, 5Cardio-Thoracic Surgery, The People's Hospital of Zhangqiu Area, Jinan, Shandong 250200; 6Department of Clinical Laboratory, Qingdao No. 9 People's Hospital, Qingdao, Shandong 266002, P.R. China

Received January 15, 2020; Accepted May 29, 2020

DOI: 10.3892/etm.2020.9045

Abstract. The aim of the present study was to investigate the role of microRNA (miR)-29b in the proliferation and migration of bone marrow mesenchymal stem cells (BMSCs) in rats with castration-induced osteoporosis and the relevant mechanisms. The gene expression profiling microarray technique was utilized to sequence the BMSCs with overexpressed miR-29b. The intersection of the potential targets and the genes downregulated in the sequencing were utilized for GO enrichment analysis. Gene set enrichment analysis (GSEA) was employed to analyze the effect of miR-29b on signaling pathways. Additionally, the effects of miR-29b overexpression on the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) and transforming growth factor-β (TGF-β)/Drosophila mothers against decapentaplegic protein (Smad) signaling pathways were detected via RT-qPCR assay and western blotting. The expression level of miR-29b was found to be significantly reduced in bone marrow tissues of postmenopausal osteoporosis patients and BMSCs of rats with castration-induced osteoporosis established via ovariectomy. Overexpression of miR-29b was able to enhance the proliferation and migration ability of BMSCs in rats with castration-induced osteoporosis, and such an enhancement may be correlated with the activation of the PI3K/AKT and TGF-β/Smad signaling pathways.

Introduction

Osteoporosis is a skeletal system disease in which mild trauma can cause fractures due to reduced bone density and destroyed bone microstructure. Hence, osteoporosis is an important risk factor for fractures (1). Osteoporotic fractures occur in the vertebral body, distal radius and proximal femur, and some patients with osteoporosis may develop systemic skeletal embrittlement (2). Osteoporosis has become a major and growing public health concern among the elderly all over the world, bringing a severe economic and health burden on elderly people (2). Osteoblast-regulated bone formation and osteoclast-regulated bone resorption play crucial roles in bone balance. Meanwhile, osteocytes, adipocytes, chondrocytes and bone marrow mesenchymal stem cells (BMSCs) in the bone microenvironment are the key sustainers of bone balance (3).

MicroRNAs (miRNAs/miRs) are non-coding RNAs with a small molecular weight (about 22 nucleotides), whose mechanism of action is to bind to the 3'-untranslated region (3'-UTR) of messenger RNAs (mRNAs) to inhibit mRNA expression or induce mRNA degradation, ultimately regulating a series

Correspondence to: Dr Niu Niu, Department of Clinical Laboratory, Qingdao No. 9 People's Hospital, 2A Chaocheng Road, Shinan, Qingdao, Shandong 266002, P.R. China
E-mail: ma4flb@163.com

*Contributed equally

Key words: miR-29, TGF-β/Smad signaling pathway, BMSCs
of important biological processes including cell proliferation, differentiation and apoptosis. Current studies have manifested that the expression level of miRNAs is evidently associated with the progression of osteoporosis. For instance, the expression levels of miR-133a and miR-422 are deemed as potential biomarkers for postmenopausal osteoporosis (5,6). Besides, it is pointed out in some studies that the expression levels of serum miR-21, miR-23a, miR-24, miR-25 and miR-100 can be used to predict the incidence rate of osteoporotic fractures. In addition, research has demonstrated that miRNAs may be key participants in the pathological process of osteoporosis (7). For example, miR-148a and miR-338 are proven in studies to be able to control bone formation, remodeling and cell differentiation during bone metabolism, thus acting as important regulators of bone density (8,9). What's more, miR-27a is demonstrated to have an influence on the progression of osteoporosis by affecting the differentiation of osteoblasts. Therefore, finding out important miRNAs modulating the pathological process of osteoporosis and investigating their mechanisms of action are of great significance for the development of a new treatment method for osteoporosis.

This study aimed to explore the role of miR-29b in osteoporosis. Previous studies have manifested that miR-29b plays a key role in the pathological and physiological processes of many diseases such as breast cancer (10), glioblastoma (11) and acute myeloid leukemia (12). More importantly, research has suggested that miR-29b participates in regulating the differentiation of osteoblasts and osteoclasts, which has promising therapeutic value for various orthopedic diseases (13).

In this study, ovariectomy was used to construct a rat model of castration-induced osteoporosis, and it was found that the overexpression of miR-29b activated the transforming growth factor-β (TGF-β) drosophila mothers against decapentaplegic protein (Smad) signaling pathway and promoted the proliferation of BMSCs in rats with castration-induced osteoporosis, thus ameliorating osteoporosis.

**Patients and methods**

**General data.** Bone marrow tissues from 25 patients with postmenopausal osteoporosis (mean age, 56 years; range, 47-62) treated at the Department of Orthopedics of Qingdao Central Hospital from May 2018 to July 2018 and 25 healthy controls (mean age, 55 years; range, 45-63) were taken as research subjects in this study. We used the posterior superior iliac spine as the puncture point and took a bone marrow biopsy to take a sample of the patient's bone marrow. These samples were immediately placed in RNA-fixer reagent (Bioteke) after collection and stored in a refrigerator at -80°C for use. To exclude the factors influencing the expression profile of miRNAs, the following exclusion criterion was used in this study: Participants in this study did not receive any drug treatment before sample collection. This study was approved by the Ethics Committee of Affiliated Hospital of Beihua University (QD. no. 2018c0102). Signed written informed consents were obtained from all participants before the study.

**Transcriptome sequencing.** Total RNAs were extracted from bone marrow tissue samples in the two groups of subjects, and then quantified using a NanoDrop kit (Thermo Fisher Scientific, Inc.). Next, the integrity of RNAs was assessed using a Bioanalyzer 2100 (Agilent Technologies, Inc.). In this study, 100 ng of total RNAs and a 3’ IVT Express kit (Agilent Technologies, Inc.) were used to prepare complimentary RNAs (cRNAs). Thereafter, the cRNAs were hybridized on a PrimeView Human microarray (Agilent Technologies, Inc.) at 45°C for 16 h according to the instructions of a GeneChip 3’ Array (Agilent Technologies, Inc.). In addition, the microarrays were processed on a FS-450 fluid station (Agilent Technologies, Inc.) for washing and staining and then scanned using a GeneChip scanner (Agilent Technologies, Inc.) according to the protocol provided by the manufacturer. The raw data of the CEL files were imported into the Partek Genomics Suite 6.6 software (Copyright, Partek Inc.), and the probe set was normalized using the Robust Multiarray Average method (14). The significance of the differentially expressed genes was determined using one-way analysis of variance (ANOVA), and the P-value was corrected using false discovery rate (FDR).

**Reverse transcription and quantitative polymerase chain reaction (RT-qPCR) assay.** RT and qPCR were used to measure the expression level of miR-29b in serum samples and large cell lines as well as the mRNA expression level of SFRP2 in HUVecs. For the RT reaction, the samples containing 500 ng of RNAs were divided into three portions, the total RNAs in each group were diluted 10 times, and 3 µl of total RNAs was utilized for PCR amplification. The amplification level of the target genes was verified using 5% agarose gel electrophoresis. The LabWorks 4.0 image acquisition and analysis software (UVP, Inc.) was applied for quantitation and data processing. In this study, U6 was used as an internal reference. Primers for the miR-29b gene were purchased from ABM (Peterborough, Camb, Canada). For each group of samples, three replicates were set to obtain reliable data. In this study, the $2^{-ΔΔCq}$ method (15) was used to analyze the changes in relative expression level of the target genes. The primer sequences used in this study are shown in Table I.

**Establishment of rat models of castration-induced osteoporosis.** This in vivo experimental scheme was approved by the Ethics Committee of Qingdao Central Hospital (QD. no. 2018b0235). A total of 10-week-old 30 Sprague-Dawley (SD) male rats weighing 180±20 g purchased from the Shanghai SLAC Laboratory Animal Center were housed in SPF animal houses routinely, with free access to water and a 12:12 h light-dark cycle. These rats were randomly divided into 2 groups, namely the experimental group (n=15) and control group (n=15), using a random number table. After 7 days of adaptive culture, the rats in the experimental group underwent bilateral ovariectomy according to the surgical plan stated in the literature (13). BMSCs were extracted from the rats in both groups after 3 months of feeding.

**Extraction of BMSCs.** After the rats were sacrificed, the femoral and tibial tissues of the rats were rapidly separated in a horizontal flow clean bench, and then the medium was applied to wash out bone marrow tissues. Then, in the horizontal flow clean bench, the bone marrow tissues were transferred to a centrifuge tube containing phosphate-buffered saline (PBS) and then carefully pipetted using a pipette to make into a cell suspension. Next, the
The BMSCs in the logarithmic growth phase were taken, uniformly inoculated into a 96-well plate at 1x10^4 cells/well, and added with MTA diluted into different concentrations, with 6 replicates set for each concentration gradient. The cells were further cultured in an incubator for 72 h, followed by the discarding of the original medium. Next, the cells were added with 20 µl of CCK-8 reaction solution (Dojindo) and 170 µl of cell medium, incubated in a dark place at 37°C for 2 h, and shaken on a micro-vibrator for 3 min. The absorbance at a wavelength of 450 nm was measured using a microplate reader (Detei, Nanjing Detei Laboratory Equipment Co., Ltd.).

**Detection of proliferation of the BMSCs via 5-ethyl-2'-deoxyuridine (EdU) assay.** The BMSCs in the logarithmic growth phase were collected and inoculated into the 96-well plate at 1x10^4 cells/well, and then (after the cells grew normally) added with miR-29b mimic or miR-con for 24 h of processing. The EdU solution was diluted with cell medium at a ratio of 1,000:1. An amount of 100 µl of 50 µM EdU medium was added into each well for 2 h of incubation and then discarded. The cells were washed with PBS twice (5 min/time), added with cell fixative (4% paraformaldehyde in PBS) (100 µl/well), incubated in the dark at room temperature on a decolorization shaker for 30 min. Next, the reaction solution was dissolved, and 100 µl of penetrant (0.5% Triton X-100 in PBS) was added for washing using the decolorization shaker for 2-3 times (10 min/time). Thereafter, the penetrant was discarded, and the cells were observed under a microscope (magnification, x200) (Yuan Ren Jian CE, Shanghai, China).

**Detection of cell migration through Transwell assay.** BMSCs (1x10^4 in volume) were cultured in a Transwell chamber (BD Biosciences; pore size, 8 µm) containing 0.2% FBS, and the Transwell chamber was embedded in a 24-well culture plate. The lower chamber was filled with fresh medium containing 10% FCS. Then, 24 h later, the cells in the lower chamber were fixed with 4% paraformaldehyde fixative solution and stained with crystal violet (0.1% (g/ml) PBS crystal violet). The ability of cell migration and invasion was detected with polycarbonate membrane Boyden chambers in a Transwell apparatus (Costar). Finally, those invasive cells were counted, and related images were captured. The values for migration and invasion were obtained by counting three fields for each membrane.

**Western blotting.** An appropriate amount of radioimmunoprecipitation assay (RIPA) (Beyotime Institute of Biotechnology) was obtained, added with the protease inhibitor phenylmethylsulfonyl fluoride (PMSF) at a ratio of 100:1 and mixed to prepare the cell lysis buffer. The cells were trypsinized, collected and added with lysis buffer, and the resulting product was collected, transferred to an Eppendorf (EP) tube, and centrifuged at 4°C and 12,500 x g for 30 min using a low temperature high-speed centrifuge, followed by collection of the protein supernatant. Thereafter, the proteins were denatured at 95°C for 10 min via thermal bath. The prepared protein samples were placed in the refrigerator at -80°C for later use. A bicinchoninic acid (BCA) kit (Pierce; Thermo Fisher Scientific, Inc.) was
adopted to quantify proteins. After that, the 10% gels for sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) were prepared, and the 20 mg protein samples were loaded into the well of the gels for electrophoresis at constant voltage (80 V) for 2.5 h. Next, the protein samples were transferred onto a polyvinylidene fluoride (PVDF) membranes (Millipore) using the semi-dry method. After that, the membrane was immersed in Tris-buffered saline with Tween®-20 (TBST) buffer containing 5% skim milk powder, and shaken slowly for 1 h for blocking. Afterwards, the antibodies were diluted with 5% skim milk powder, and the membrane was incubated with the primary antibodies (all from Abcam) (rabbit anti-pan-AKT antibody (dilution, 1:500; cat. no. ab8805), rabbit anti-pan-AKT (phospho-T308) antibody (dilution, 1:500; cat. no. ab8933), rabbit anti-Smad2 + Smad3 antibody (dilution, 1:1,000, cat. no. ab202445), rabbit anti-Smad2 + Smad3 (phospho T8) antibody (dilution, 1:1000, cat. no. ab272332), rabbit anti-β-actin antibody (dilution, 1:1,000, cat. no. ab8227) and rinsed with TBST solution for 3 times (10 min/time). Next, the membrane was incubated with secondary antibody [goat anti-rabbit (HRP) IgG antibody (dilution, 1:2,000; cat. no. ab6721)] at room temperature for 2 h and rinsed twice with TBST and once with TBS (10 min/time). Electrochemiluminescence (ECL) reagents were used to detect proteins, with exposure in a dark room. The relative expression level of proteins was analyzed by Image-Pro Plus v6 (Media Cybernetics).

**Statistical analysis.** Statistical Product and Service Solutions (SPSS) 13.0 software (SPSS Inc.) was employed for statistical analysis. Data are expressed as mean ± standard deviation. One-way analysis of variance (ANOVA) with post hoc pairwise analysis (Least Significant Difference) was used for comparison among groups. *P*<0.05 suggested that the difference was statistically significant.

**Results**

*Expression level of miR-29b in bone marrow tissues of patients with postmenopausal osteoporosis is significantly decreased.* The results of the expression profile screening illustrated that the expression profile of miRNAs in bone marrow tissues of postmenopausal osteoporosis patients (OP) was obviously different from that of healthy controls (Con) (Fig. 1A), and that 74 miRNAs in the bone marrow tissues exhibited notable differences between postmenopausal osteoporosis patients and healthy controls (fold change >2; *P*<0.01). In addition, an obvious difference was found in the expression level of miR-29b in bone marrow tissues between postmenopausal osteoporosis patients and healthy controls. Some studies have manifested that the expression level of miR-29b in postmenopausal osteoporosis patients has an obvious correlation with the morphological parameters of bone formation and bone microstructural parameters and may play a crucial role in the pathophysiological process of patients with postmenopausal osteoporosis (13,14) Considering the reliability of the high-throughput screening technology, miR-29b was subsequently selected as the research object in this study, and the more reliable RT-qPCR assay was carried out for further verification. The results of RT-qPCR assay showed that the expression level of miR-29b in bone marrow...
tissues was markedly lower in 25 patients with postmenopausal osteoporosis (OP) than that in healthy controls (Con), showing a statistically significant difference (P<0.01) (Fig. 1B).

**Identification and culture of BMSCs in rats with osteoporosis.** After the primary culture for 5 days, the number of red blood cells and that of other suspended cells were markedly reduced. The morphology of the BMSCs primarily cultured is shown in Fig. 2A. Then, two BMSC-specific markers were applied to distinguish BMSCs from hemocytes and other monocytes. Based on the results of flow cytometry, the proportion of cluster of differentiation (CD)-44 positive cells in the BMSCs cultured was 99.7%, and that of CD45-positive cells was only 0.17%, implying that BMSCs had relatively high purity, and further tests were able to be performed (Fig. 2B).

**Flow cytometry.** Flow cytometry was applied for determining cell apoptosis with Annexin V fluorescein isothiocyanate (FITC) Apoptosis Measurement kit (BD Biosciences). Twenty four hours after transfection, the cells were collected and washed twice by cold PBS. Cells (10⁶) were suspended in 200 µl binding buffer containing 5 µl propidium iodide (PI) and 10 µl Annexin-FITC. Then cells were incubated for 30 min in the dark. Finally, cells were detected by flow cytometry analysis (Beckman Coulter).

**Overexpression of miR-29b enhances the proliferation and migration capability of BMSCs in rats with osteoporosis.** The expression of miR-29b was significantly increased in the BMSC + miR-29b group, indicating successful transfection of miR-29b (Fig. 3A). It was found through CCK-8 assay that the proliferation of BMSCs was evidently enhanced at 12, 24, 36, 48 and 72 h in the BMSC + miR-29b group when compared with the BMSC + miR-con group, suggesting that miR-29b can promote the proliferation of BMSCs in rats with castration-induced osteoporosis (P<0.01 from 24 h) (Fig. 3B). In addition, EdU staining results demonstrated that the number of red fluorescence-labeled cells was increased overtly after 72 h of miR-29b overexpression with the BMSC + miR-con group, implying that miR-29b expression facilitates the proliferation of BMSCs in rats with castration-induced osteoporosis (Fig. 3C).

Moreover, compared with that in the control group, the migration ability of BMSCs was clearly weakened in rats with castration-induced osteoporosis, but obviously strengthened in the BMSC + miR-29b group, indicating that the overexpression of miR-29b promotes the migration of BMSCs in rats with castration-induced osteoporosis (Fig. 3D).

**Potential targets of miR-29b are enriched in biological processes of cell proliferation and migration.** To discover the potential mechanism of action of miR-29b, a two-step method was adopted to exploit the potential targets of miR-29b. Firstly, bioinformatics software Targetscan and miRanda were used to predict the potential targets of miR-29b (16,17), based on which, 1,113 potential targets of miR-29b were obtained. Next, expression profile microarray technique was employed to identify the markedly reduced genes in BMSCs with overexpression of miR-29b. A total of 432 reduced mRNAs were
WA NG et al.: miR-29b ENHANCES PROLIFERATION AND MIGRATION OF BMSCs IN OSTEOPOROSIS

obtained. After taking the intersection of the 1,113 potential targets and the 432 markedly reduced mRNAs, 76 potential targets of miR-29b were obtained.

Next, these 76 potential targets were subjected to Gene Ontology (GO) enrichment analysis. The results revealed that the potential targets of miR-29b were overtly enriched in signaling pathways including cell proliferation, regulation of cell proliferation, cell cycle, cell migration and cell adhesion (Fig. 4A). To investigate the potential mechanism of action of miR-29b in affecting BMSC proliferation and migration in rats with osteoporosis, protein-protein interaction (PPI) networks for cell proliferation and cell migration regulated by miR-29b was constructed using STRING software (17) (Fig. 4B). Interestingly, gene of phosphate and tension homology deleted on chromosome ten (PTEN) was the core protein in the PPI networks for both cell proliferation

Figure 3. Overexpression of miR-29b enhances proliferation and migration capabilities of BMSCs in rats with osteoporosis. (A) The expression level of miR-29b was increased in the BMSC + miR-29b group when compared with the Control group via RT-qPCR assay. **P<0.01 vs. the control group. (B) Effect of the overexpression of miR-29b on proliferation ability of BMSCs in rats with osteoporosis as detected through CCK-8 assay. **P<0.01 vs. the BMSC + miR-con group. (C) Effect of overexpression of miR-29b on proliferation of BMSCs in rats with osteoporosis as detected via EdU staining assay. (D) Effect of overexpression of miR-29b on migration of BMSCs in rats with osteoporosis as detected through Transwell assay. BMSCs, bone marrow mesenchymal stem cells.
and cell migration, implying that the miR-29b may affect the proliferation and migration of BMSCs in rats with osteoporosis by targeting PTEN. At present, many studies have pointed out that PTEN is a direct target of miR-29b (13,14).

Overexpression of miR-29b activates phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) and transforming growth factor-β (TGF-β)/drosophila mothers against decapentaplegic protein (Smad) signaling pathways. It was discovered through gene set enrichment analysis (GSEA) (18) that the PI3K/AKT and TGF-β/Smad signaling pathways were downregulated in BMSCs in comparison with those in the BMSC + miR-29b group (Fig. 5).

Effects of miR-29b overexpression on PI3K/AKT and TGF-β/Smad signaling pathway-related genes determined through RT-qPCR assay. To further investigate the precise mechanism of action of miR-29b in affecting the proliferation

Figure 4. Potential targets of miR-29b are enriched in biological processes of cell proliferation and migration. (A) Results of GO enrichment for potential targets of miR-29b. (B) PPI network of miR-29b potential targets involved in biological processes of cell proliferation and migration. GO, Gene Ontology; PPI, protein-protein interaction.
and migration of BMSCs in the rats with osteoporosis, and to verify the results of the bioinformatics analysis, RT-qPCR assay was conducted to verify the effect of the expression level of miR-29b on the mRNA expression levels of the PI3K/AKT and TGF-β/Smad signaling pathway-related genes. The results revealed that, in comparison with the miR-con group, the BMSC + miR-29b group exhibited significantly elevated expression levels of AKT and PI3K in BMSCs, and the differences were statistically significant (P<0.01). Moreover, compared with levels in the BMSC + miR-con group, the expression levels of TGF-β1 and Smad3 in BMSCs were significantly increased, while the expression level of Smad7 was significantly reduced in the BMSC + miR-29b group, and the differences were of statistical significance (P<0.01) (Fig. 6).

Effects of miR-29b overexpression on the TGF-β/Smad signaling pathway as determined by western blotting. The results of western blotting illustrated that in comparison with the BMSC + miR-con control group, the BMSC + miR-29b group had notably elevated expression level of phosphorylated (p)-AKT/AKT and markedly increased expression level of p-Smad2/3/Smad2/3, and the differences were statistically significant (P<0.01) (Fig. 7).

Discussion

Multiple studies have pointed out that postmenopausal osteoporosis has a complex pathological mechanism (1,2). In the pathological processes of osteoporosis, osteocytes, adipocytes, chondrocytes and bone marrow mesenchymal stem cells (BMSCs) in the bone microenvironment are key roles maintaining bone balance (3). BMSCs are fibroblast-like cells with the ability to differentiate into various types of cells including osteoblasts, chondrocytes and adipocytes. Studies have manifested that the proliferation ability of BMSCs is significantly weakened in osteoporosis patients (2,3) However, the understanding of such a weakening is still very limited. At present, numerous studies have indicated that miRNAs are not only pivotal regulators in BMSC differentiation, but also of important significance in the proliferation and apoptosis of BMSCs (5-7).

According to the results of this study, it can be seen that miR-29b plays a key role in regulating BMSC proliferation and migration. First, our results showed that the miR-29b expression level was significantly reduced in bone marrow tissues of postmenopausal osteoporosis patients and BMSCs of rats with castration-induced osteoporosis constructed via ovariectomy. Studies have displayed that the expression level of miR-29b significantly declines in patients with postmenopausal osteoporosis, and the lower the expression level of miR-29b is, the worse the bone status of patients with osteoporosis will be (13,14). This is in line with the findings of this study (19).

To discover the potential mechanism of action of miR-29b, a two-step method was used to exploit the potential targets of miR-29b. Firstly, bioinformatics software Targetscan and miRanda were used to predict the potential targets of miR-29b, based on which, 1,113 potential targets of miR-29b were obtained. Next, expression profile microarray technique was employed to identify the downregulated genes in BMSCs with overexpression of miR-29b. A total of 432 markedly reduced mRNAs were obtained. After taking the intersection of the 1,113 potential targets and the 432 reduced mRNAs, 76 potential targets of miR-29b were obtained, which were then subjected to GO enrichment analysis. The results of GO enrichment analysis revealed that the potential targets of miR-29b were overexpressed in signaling pathways including cell proliferation, regulation of cell proliferation, cell cycle, cell migration and cell adhesion. The results of CCK-8 and EdU assays showed that overexpression of miR-29b overtly promoted the proliferation of BMSCs in rats with castration-induced
osteoporosis. Moreover, the Transwell assay results revealed the overexpression of miR-29b significantly facilitated the migration of BMSCs in rats with castration-induced osteoporosis. A previous study demonstrated that in breast cancer cells, the expression level of miR-29b was significantly higher in the MDA-MB-231 cell line than that in MCF-7 cell line, suggesting that MDA-MB-231 has stronger proliferation and migration ability than MCF-7 cell line, and inhibiting the expression of miR-29b can overtly weaken the proliferation and migration capability of MDA-MB-231 cells (20). This is consistent with the findings of this study and proves the reliability of the findings of this study.

Interestingly, in the PPI network for cell proliferation and cell migration regulated by miR-29b constructed in this study, PTEN was the core gene, indicating that PTEN is a key participant in the activation of BMSC proliferation and migration by miR-29b in rats with castration-induced osteoporosis. A large number of existing studies have confirmed that PTEN is
a direct target of miR-29b (21,22). The degradation of PTEN is capable of enhancing the activation of the PI3K/AKT signaling pathway, and research has pointed out that the PI3K/AKT signaling pathway is a critical regulation signaling pathway for the proliferation and migration of cells (23,24). The results of RT-qPCR assay and western blotting showed that the expression level of p-AKT/AKT in BMSCs was dramatically increased in the BMSC + miR-29b group compared with that in the miR-con group, suggesting that miR-29b can activate the PI3K/AKT signaling pathway. Interestingly, bioinformatic analysis revealed that the TGF-β/Smad signaling pathway was also activated in BMSCs in the BMSC + miR-29b group. In accordance with some studies, in mouse embryonic osteoblast precursor cells, liraglutide activates the PI3K/AKT signaling pathway to induce the activation of the TGF-β/Smad signaling pathway, suggesting that the PI3K/AKT signaling pathway may have a regulatory relationship with the TGF-β/Smad signaling pathway (25,26). Given this, it was hypothesized in this study that miR-29b degrades PTEN protein expression to enhance the activation of the PI3K/AKT signaling pathway and thus lead to the activation of the TGF-β/Smad signaling pathway, thereby promoting the proliferation and migration of BMSCs in rats with castration-induced osteoporosis.

There are some shortcomings in this study. First, whether miR-29b enhances the proliferation and migration ability of BMSCs in rats with castration-induced osteoporosis by specifically activating the PI3K/AKT signaling pathway was undetermined. What's more, direct evidence that activation of the PI3K/AKT signaling pathway leads to activation of the TGF-β/Smad signaling pathway is still lacking. Further studies focusing on the molecular mechanisms are underway. In addition, the effect of miR-29b on osteogenesis differentiation will be investigated in our future research.

In conclusion, it was found in this study that the expression level of miR-29b is evidently lower in bone marrow tissues of postmenopausal osteoporosis patients and BMSCs of rats with castration-induced osteoporosis established via ovariectomy. miR-29b overexpression enhanced the proliferation and migration ability of BMSCs in rats with castration-induced osteoporosis, and the enhancement of the proliferation and migration ability may be correlated with the activation of the PI3K/AKT and TGF-β/Smad signaling pathways.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

The datasets used during the present study are available from the corresponding author upon reasonable request.

Authors' contributions

YW, XK and NN designed the study and performed the experiments. YW and TZ established the animal models. XH and PK collected the data. NN and WJ analyzed the data. YW, PK, XH and NN prepared the manuscript. All authors read and approved the manuscript and agree to be accountable for all aspects of the research in ensuring that the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Ethics approval and consent to participate

This study was approved by the Ethics Committee of the Affiliated Hospital of Beihua University (Jilin, Jilin, China). Signed written informed consents were obtained from the patients and/or guardians. The animal study was approved by the Animal Ethics Committee of Affiliated Hospital of Beihua University Animal Center (Jilin, Jilin, China).

Patient consent for publication

Patients or their guardians have provided written informed consents for publication.

Competing interests

The authors declare no competing interests.

References

1. Black DM and Rosen CJ: Postmenopausal osteoporosis. N Engl J Med 374: 2096-2097, 2016.
2. Qiao L, Liu D, Li CG and Wang YJ: MiR-203 is essential for the shift from osteogenic differentiation to adipogenic differentiation of mesenchymal stem cells in postmenopausal osteoporosis. Eur Rev Med Pharmacol Sci 22: 5804-5814, 2018.
3. Jing H, Liao L, Su X, Shuai Y, Zhang X, Deng Z and Jin Y: Declining histone acetyltransferase GCN5 represses BMSC-mediated angiogenesis during osteoporosis. FASEB J 31: 4422-4433, 2017.
4. Paraskevopoulou MD and Hatzigeorgiou AG: Analyzing miRNA-lncRNA interactions. Methods Mol Biol 1402: 271-286, 2016.
5. Li Z, Zhang W and Huang Y: MiRNA-133a is involved in the regulation of postmenopausal osteoporosis through promoting osteoclast differentiation. Acta Biochim Biophys Sin (Shanghai) 50: 273-280, 2018.
6. Letarouilly JG, Broux O and Clabaut A: New insights into the epigenetics of osteoporosis. Genomics 111: 793-798, 2019.
7. Seeliger C, Karpinski K, Haug AT, Vester H, Schmitt A, Bauer JS and van Griensven M: Five freely circulating miRNAs and bone tissue miRNAs are associated with osteoporotic fractures. J Bone Miner Res 29: 1718-1728, 2014.
8. Bedene A, Menccej Bedrač S, Češ T, Marc J, Vrtačnič P, Prželj J, Kocjan T, Kranjc T and Ostanek B: MiR-148a the epigenetic regulator of bone homeostasis is increased in plasma of osteoporotic postmenopausal women. Wien Klin Wochenschr 128 (Suppl 7): S519-S526, 2016.
9. Guo DW, Han YX, Cong L, Liang D and Tu GF: Resveratrol prevents osteoporosis in ovariectomized rats by regulating microRNA-338-3p. Mol Med Rep 12: 2098-2106, 2015.
10. Wang C, Bian Z, Wei D and Zhang JG: miR-29b regulates migration of human breast cancer cells. Mol Cell Biochem 352: 197-207, 2011.
11. Cortez MA, Nicoloso MS, Shimizu M, Rossi S, Gopisetty G, Molina JR, Carlotti CJ, Tirapelli D, Neder L, Brassecos MS, et al: miR-29b and miR-125a regulate podoplanin and suppress invasion in glioblastoma. Genes Chromosomes Cancer 49: 981-990, 2010.
12. Garzon R, Heaphy CE, Havelange V, Fabbri M, Volinia S, Tsao T, Zanesi N, Kornblau SM, Marcucci G, Calin GA, et al: MicroRNA 29b functions in acute myeloid leukemia. Blood 114: 5331-5341, 2009.
13. Zeng Q, Wang Y, Gao J, Yan Z, Li Z, Zou X, Li Y, Wang J and Guo Y: miR-29b-3p regulated osteoblast differentiation via regulating IGF-1 secretion of mechanically stimulated osteocytes. Cell Mol Biol Lett 24: 11, 2019.
14. McCall MN, Bolstad BM and Irizarry RA: Frozen robust multi-array analysis (fRMA). Biostatistics 11: 242-253, 2010.
15. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
16. Friedman RC, Farh KK, Burge CB and Bartel DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19: 92-105, 2009.
17. Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, et al: The STRING database in 2017: Quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res 45: D362-D368, 2017.
18. Mootha VK, Lindgren CM, Eriksson A, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, et al: PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34: 267-273, 2003.
19. Mathavan N, Turunen MJ, Tägil M and Isaksson H: Characterising bone material composition and structure in the ovariectomized (OVX) rat model of osteoporosis. Calcif Tissue Int 97: 134-144, 2015.
20. Rossi M, Pitari MR, Arnodio N, Di Martino MT, Conforti F, Leone E, Botta C, Paolinio FM, Del Giudice T, Iuliano E, et al: miR-29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma-related bone disease. J Cell Physiol 228: 1506-1515, 2013.
21. Zhang B, Shetti D, Fan C and Wei K: miR-29b-3p promotes progression of MDA-MB-231 triple-negative breast cancer cells through downregulating TRAF3. Biol Res 52: 38, 2019.
22. Yu F, Chen B, Dong P and Zheng J: HOTAIR epigenetically modulates PTEN expression via microRNA-29b: A novel mechanism in regulation of liver fibrosis. Mol Ther 25: 205-217, 2017.
23. Yan B, Guo Q, Fu FJ, Wang Z, Yin Z, Wei YB and Yang JR: The role of miR-29b in cancer: Regulation, function, and signaling. Oncotargets Ther 8: 539-548, 2015.
24. Dong Y, Liang Q, Yuan B, Yang C, Gao R and Zhou X: MALAT1 promotes the proliferation and metastasis of osteosarcoma cells by activating the PI3K/Akt pathway. Tumour Biol 36: 1477-1486, 2015.
25. Jin Y, Chen W, Yang H, Yan Z, Lai Z, Feng J, Peng J and Lin J: Scutellaria barbata D: Don inhibits migration and invasion of colorectal cancer cells via suppression of PI3K/AKT and TGF-β/Smad signaling pathways. Exp Ther Med 14: 5527-5534, 2017.
26. Wu S, Wang Y, Yuan Z, Wang S, Du H, Liu X, Wang Q and Zha X: Human adipose-derived mesenchymal stem cells promote breast cancer MCF7 cell epithelial-mesenchymal transition by cross interacting with the TGFβ/Smad and PI3K/AKT signaling pathways. Mol Med Rep 19: 177-186, 2019.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.